Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function

Madhusudhanan Sukumar,1 Jie Liu,2 Yun Ji,3 Murugan Subramanian,4 Joseph G. Crompton,1 Zhiya Yu,1 Rahul Roychoudhuri,1 Douglas C. Palmer,1 Pawel Muranski,1 Edward D. Karoly,5 Robert P. Mohney,6 Christopher A. Klebanoff,1,6 Ashish Lal,4 Toren Finke,2 Nicholas P. Restifo,1 and Luca Gattinoni3

1Center for Cancer Research, Surgery Branch, National Cancer Institute, 2Center for Molecular Medicine, National Heart, Lung, and Blood Institute, 3Center for Cancer Research, Experimental Transplantation and Immunology Branch, National Cancer Institute, and 4Center for Molecular Genetics, NIH, Bethesda, Maryland, USA. 5Metabolon Incorporated, Durham, North Carolina, USA. 6Clinical Investigator Development Program, National Cancer Institute, NIH, Bethesda, Maryland, USA.

Naive CD8+ T cells rely upon oxidation of fatty acids as a primary source of energy. After antigen encounter, T cells shift to a glycolytic metabolism to sustain effector function. It is unclear, however, whether changes in glucose metabolism ultimately influence the ability of activated T cells to become long-lived memory cells. We used a fluorescent glucose analog, 2-NBDG, to quantify glucose uptake in activated CD8+ T cells. We found that cells exhibiting limited glucose incorporation had a molecular profile characteristic of memory precursor cells and an increased capacity to enter the memory pool compared with cells taking up high amounts of glucose. Accordingly, enforcing glycolytic metabolism by overexpressing the glycolytic enzyme phosphoglycerate mutase-1 severely impaired the ability of CD8+ T cells to form long-term memory. Conversely, activation of CD8+ T cells in the presence of an inhibitor of glycolysis, 2-deoxyglucose, enhanced the generation of memory cells and antitumor functionality. Our data indicate that augmenting glycolytic flux drives CD8+ T cells toward a terminally differentiated state, while its inhibition preserves the formation of long-lived memory CD8+ T cells. These results have important implications for improving the efficacy of T cell–based therapies against chronic infectious diseases and cancer.

Introduction

CD8+ T cells play an important role in the adaptive immune response to intracellular pathogens and cancer (1, 2). After stimulation with cognate antigen, CD8+ naive T cells (Tns) clonally expand and differentiate into effector T cells (Teffs) and distinct memory T cell subsets, including stem cell memory T cells (Tscms), central memory T cells (Tcms), and effector memory T cells (Temss) (3). These subsets can be identified by distinct cell surface marker expression and gene expression profiles that enable their functional specialization (3). Preclinical studies using adoptive transfer of purified CD8+ T cell populations have revealed that less-differentiated Tscms and Tcms can mediate enhanced antitumor (4, 5) and antiviral (6) responses compared with more-differentiated Temss and Teffs, due to increased proliferative and survival capacities. Thus, there has been considerable interest in understanding the molecular mechanisms governing the formation of long-lived memory T cell subsets to enable the development of more potent immunotherapies against cancer and infectious diseases (3, 7, 8).

Recent findings have highlighted the importance of cellular metabolism in regulating CD8+ T cell differentiation and memory formation (9–12). Metabolic profiling and functional analyses have shown that Tns rely on oxidation of fatty acids (FAO) as a primary source of energy (11, 13, 14). After antigen encounter, however, T cells shift to glycolytic metabolism to sustain effector function (15–18). Similar to Tns, memory CD8+ T cells use FAO to meet their energy demands (19, 20). For instance, CD8+ T cells deficient in TNF receptor–associated factor 6 (Traf6) exhibit defective FAO and fail to form physiological numbers of memory T cells after infection (21). Conversely, enforcing FAO either by overexpressing carnitine palmitoyltransferase 1a (Cpt1a), a rate-limiting enzyme in FAO (22), or by inhibiting activity of the mammalian target of rapamycin (mTOR) resulted in increased numbers of memory CD8+ T cells (21, 23). However, it remains unclear whether immunological memory is regulated by metabolic pathways other than FAO.

Here, we show that induction of high glycolytic activity in CD8+ T cells severely compromises the generation of long-lived memory cells by driving T cells toward a terminally differentiated state. We found that CD8+ T cells taking up high amounts of glucose had a molecular profile characteristic of short-lived effectors and failed to survive upon adoptive transfer. Consistent with these findings, skewing cellular metabolism toward glycolysis by overexpressing the glycolytic enzyme phosphoglycerate mutase-1 (Pgam1) impaired the ability of CD8+ T cells to form long-term memory. Conversely, experiments using the glucose analog 2-deoxyglucose (2DG), an inhibitor of hexokinase-2 (Hk2), indicated that limiting glycolysis in CD8+ T cells favors the establishment of immunological memory. Most importantly, treatment of tumor-specific CD8+ T cells with 2DG enhanced their capacity to trigger the destruction of established tumors. Direct blockade of glycolysis using 2DG was associated with enhanced expression and activity of transcription factors regulating memory versus effector differentiation in CD8+ T cells, providing a link between metabolism and transcriptional regulation of cell fate determination.
Results

Metabolic reprogramming upon CD8+ T cell differentiation. Activation of CD8+ T cells is accompanied by effector differentiation and the loss of memory potential in the majority of cells. To explore the metabolic changes that occur during this process, we first evaluated the gene expression of key rate-limiting enzymes involved in FAO and glycolysis in pmel-1 CD8+ Tn and Teff subsets. Data are mean ± SEM of 6 independently generated samples. G-6-P, glucose 6 phosphate; PEP, phosphoenolpyruvate. (C) OCR and ECAR of pmel-1 CD8+ Tns and Teffs. Data are mean ± SEM of 4 measurements. **P < 0.01, ****P < 0.0001, 2-tailed Student’s t test. Results in A and C are representative of 3 independent experiments.

Figure 1

CD8+ T cells undergo metabolic reprogramming upon activation and differentiation. (A) Quantitative RT-PCR analysis of Cpt1a and Hk2 expression in pmel-1 CD8+ T cells at the indicated times after T cell stimulation. Results are presented relative to Actb. Data are mean ± SEM of 3 measurements. (B) Relative abundance of key metabolites involved in FAO and glycolysis in pmel-1 CD8+ Tn and Teff subsets. Data are mean ± SEM of 6 independently generated samples. G-6-P, glucose 6 phosphate; PEP, phosphoenolpyruvate. (C) OCR and ECAR of pmel-1 CD8+ Tns and Teffs. Data are mean ± SEM of 4 measurements. **P < 0.01, ****P < 0.0001, 2-tailed Student’s t test. Results in A and C are representative of 3 independent experiments.

Glucose uptake segregates short-lived Teffs from memory T cell precursors. Although these data indicated that activation and effector differentiation of CD8+ T cells was associated with dramatic increases in glycolysis and lactate production, it remained to be determined whether these changes in glucose metabolism could ultimately influence the ability of activated T cells to become long-lived memory cells. To separate activated CD8+ T cells based on intrinsic differences in glycolytic activities, we used a fluorescent glucose analog, 2-(N-[7-nitrobenz-2-oxa-1,3-diazol-4-yl]amino)-2-deoxyglucose (2-NBDG), which allows for direct quantification of glucose incorporation in living cells by flow cytometry (24, 25). We stimulated pmel-1 splenocytes with cognate antigen gp100 and IL-2 to induce effector differentiation (26) and isolated T cells with low and high 2-NBDG uptake (2-NBDGlo and 2-NBDBGhi, respectively) by flow cytometry sorting (Figure 2A). Uptake of radiolabeled 2DG confirmed that 2-NBDG uptake discriminated cells based on their capacity to incorporate glucose (Figure 2B). 2-NBDBGlo T cells had increased mRNA levels of solute carrier family 2 (Slc2a1; which encodes the glucose transporter Glut-1) and Hk2 compared with 2-NBDBGlo cells (Supplemental Figure 3), which suggests that this fluorescent glucose analog could efficiently distinguish cells with differential glucose metabolism. Furthermore, cells labeling intensely with 2-NBDG displayed greater ECAR than did their 2-NBDBGlo counterparts (Figure 2C), which indicates that differential 2-NBDBGlo uptake reflects functional differences in glycolytic metabolism. Interestingly, 2-NBDBGlo T cells displayed a higher OCR/ECAR ratio (Figure 2D), which suggests that these cells preferentially used OXPHOS compared with 2-NBDBGlo cells. However, this difference in OCR/ECAR ratio was driven by the denominator, as basal OCR was lower in 2-NBDBGlo cells (Supplemental Figure 4A). These functional studies indicated that 2-NBDBGlo cells have increased energetic demand compared to...
with 2-NBDG\textsuperscript{hi} cells, which appear more metabolically quiescent. Accordingly, forward scatter (FSC) and side scatter (SSC) measurements of these 2 populations revealed that 2-NBDG\textsuperscript{hi} cells were blastic and highly granular, whereas 2-NBDG\textsuperscript{lo} cells appeared smaller in size (Supplemental Figure 4B). Notably, these metabolic differences were not merely due to lack of proper Tn stimulation. Indeed, dilution of the cell proliferation dye eFluor670 and measurement of the T cell activation markers CD44, CD25, and CD69 revealed that 2-NBDG\textsuperscript{lo} cells had undergone extensive proliferation and activation after priming (Supplemental Figure 5).

To evaluate whether differences in glucose metabolism in CD8\textsuperscript{T} cells are associated with differences in transcriptional regulation of T cell differentiation, we quantified the mRNA levels of key transcription factors and molecules associated with either memory precursors or short-lived, terminally differentiated Teffs in 2-NBDG\textsuperscript{hi} and 2-NBDG\textsuperscript{lo} cells (8). We found that the Wnt-β-catenin signaling transducers transcription factor 7 (Tcf7), lymphoid enhancer factor 1 (Lef1), and B cell CLL/lymphoma 6 (Bcl6), which promote memory CD8\textsuperscript{T} cell formation (4, 27–29), were significantly overexpressed in 2-NBDG\textsuperscript{lo} versus 2-NBDG\textsuperscript{hi} CD8\textsuperscript{T} cells (Figure 2E). In contrast, PR domain containing 1, with ZNF domain (Prdm1) — which encodes B lymphocyte–induced maturation protein-1 (Blimp-1), a master regulator of terminal differentiation (30–33) — was enriched in 2-NBDG\textsuperscript{hi} cells compared with their 2-NBDG\textsuperscript{lo} counterparts (Figure 2E). In addition, perforin (Prf1) and granzyme B (Gzmb), which encode key cytotoxic effector molecules, were also highly expressed in 2-NBDG\textsuperscript{lo} cells (Figure 2E). Thus, glucose uptake enabled the segregation of T cells that had molecular profiles associated with Teffs (2-NBDG\textsuperscript{hi}) and memory precursor cells (2-NBDG\textsuperscript{lo}).

Given these findings, we sought to ascertain whether glucose uptake could also be used to segregate T cells with differential capacity to establish memory in vivo. We adoptively transferred 2-NBDG\textsuperscript{hi} and 2-NBDG\textsuperscript{lo} cells into wild-type mice, which were then infected with a recombinant strain of vaccinia virus encoding the cognate antigen gp100 (referred to herein as gp100-VV). Strikingly, cells that experienced an increased rate of glucose metabolism exhibited poor engraftment, proliferation, and survival capacities compared with 2-NBDG\textsuperscript{lo} cells, which exhibited 10- to 100-fold higher frequency over the time course of infection (Figure 2, F and G). Taken together, these findings indicated that during T cell activation, there is heterogeneous induction of glycolysis: cells that uptake high levels of glucose becoming short-lived Teffs, whereas cells that maintain reduced glucose incorporation preferentially form memory.

Constitutive activation of glycolytic flux limits CD8\textsuperscript{T} cell memory development. To determine whether high glycolytic flux is merely...
associated with cells with an impaired capacity to become memory or, rather, is causally related to the observed defect in CD8+ T cell memory formation, we used a genetic approach to enforce glycolytic metabolism. We transduced CD8+ T cells with the glycolytic enzyme Pgam1, which has been shown to enhance glycolytic flux (34, 35) and modulate the cellular lifespan of primary mouse embryonic fibroblasts (35). Pgam1-overexpressing cells were isolated based on the expression of the reporter marker GFP and compared with control cells engineered to express GFP alone (Figure 3A). Enforced expression of Pgam1 induced CD8+ T cells to adopt a predominantly glycolytic phenotype, as revealed by augmented uptake of radiolabeled 2DG, increased ECAR levels, and lower OCR/ECAR ratio compared with controls (Figure 3, B–D).

To explore whether ectopic expression of Pgam1 influences CD8+ T cell differentiation in vivo, we adoptively transferred Pgam1-overexpressing pmel-1 CD8+ T cells into wild-type mice and subsequent infection with gp100-VV. Density plots in E are shown after gating on CD8+ cells. Numbers represent percent cells in the GFP+ gate. Data in E are mean ± SEM of 3 samples. (G and H) Flow cytometry analysis (G) and number (H) of CD8+GFP+ T cells in mice as in E and F, 5 days after heterologous vaccination with ad-gp100. Density plots in G are shown after gating on CD8+ cells. Numbers represent percent cells in the GFP+ gate. *P < 0.05, **P < 0.01, 1-tailed (C and D) or 2-tailed (B, F, and H) Student’s t test.

Data are representative of 5 (A) or 2 (B–H) independent experiments.

Inhibition of glycolysis enhances memory CD8+ T cell formation. Our experiments using adoptive transfer of CD8+ T cells with intrinsic differences in glucose metabolism and studies using a genetic approach to augment glycolytic function indicated that CD8+ T cells displaying higher glycolytic flux had a limited capacity to establish immunological memory. It remained to be addressed,
Figure 4
Inhibition of glycolysis triggers activation of energy stress signaling, which reinforces glycolysis shutdown. (A) ECAR and OCR/ECAR ratio of CD8+ T cells activated by antibodies specific to CD3 and CD28 in the presence of 2DG (2 mM) or DMSO vehicle. Data are mean ± SEM of 4 measurements. (B) Immunoblot analysis of p-AMPK and Hif1-α protein in cells as in A. β-actin was used as a loading control. (C) Quantitative RT-PCR analysis of the expression of glycolytic enzymes in CD8+ T cells. Results are presented relative to Actb. Tpi, triose phosphate isomerase; Pkm2, pyruvate kinase muscle; Slc16a3, solute carrier family 16, member 3; Ldha, lactate dehydrogenase A. Data are mean ± SEM of 3 measurements. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, 1-tailed (A, OCR/ECAR) or 2-tailed (A, ECAR, and C) Student’s t test. Data are representative of 3 (C) or 2 (A and B) independent experiments.

Inhibition of glycolysis during T cell priming programs CD8+ T cells to adopt a diverse fate in vivo, we transferred 2DG-treated pmel-1 CD8+ T cells into wild-type mice infected with gp100-VV and evaluated the expansion, persistence, and phenotypic changes of transferred cells. 2DG-treated CD8+ T cells expanded robustly, as indicated by increased frequencies and numbers of CD8+ Thy-1.1+ T cells in the spleen at the peak of the immune response compared with control cells (P < 0.01; Supplemental Figure 10, A and B). Despite increased expansion, a higher proportion of 2DG-treated cells retained a memory phenotype, whereas the majority of control CD8+ T cells underwent terminal differentiation, as revealed by the loss of CD62L and concomitant acquisition of the senescence marker KLRG-1 (Supplemental Figure 10, C and D). These quantitative and qualitative differences between 2DG-treated T cells and controls became more prominent during the memory phase of immune response. We observed 100-fold higher frequencies of pmel-1 CD8+ T cells in both lymphoid and nonlymphoid tissues of animals that received adoptive transfer of 2DG-treated versus control T cells (Figure 5, B and C). Notably, the persisting progeny of T cells primed in the presence of 2DG were relatively enriched in Tcms compared with control cells, which preferentially gave rise to senescent KLRG-1+ T cells (Figure 5D). Consistent with these findings, recall responses were significantly increased in mice that received adoptive transfer of 2DG-treated T cells (Figure 5, E and F). Together, these findings indicate that specific inhibition of glycolysis during priming enhances not only the quantity, but also the quality, of antigen-specific memory CD8+ T cells.

Inhibition of glycolysis sustains Foxo1 activity and enhances lymphoid homing. Recent studies have demonstrated the importance of Foxo1 in regulating memory versus effector lineage commitment in CD8+ T cells (20, 41, 42). To determine whether inhibition of glucose metabolism in CD8+ T cells regulated Foxo1 activity, we first evaluated Foxo1 phosphorylation in differentiating CD8+ T cells stimulated in the presence or absence of 2DG. Stimulation of CD8+ T cells induced phosphorylation of Foxo proteins at T24/T36 residues, a process that was prevented by 2DG treatment.

However, whether direct inhibition of glycolysis would conversely enhance T cell survival and the capacity to form long-lived memory cells. To directly target the glycolytic pathway in CD8+ T cells, we used the Hk2 inhibitor 2DG. Previous reports have demonstrated that cell proliferation was blocked by high concentrations of 2DG (50 mM) (36). However, low doses of 2DG have been used to address the role of glycolysis in directing the fate decision of CD4+ Th17 cells versus Foxp3+ Tregs (37, 38). Based on these findings and titration experiments (Supplemental Figure 7), we chose a 2-mM dose for the present study. Activation of CD8+ T cells in the presence of 2DG was sufficient to inhibit glycolytic flux and dramatically reduce lactate production, as revealed by measurement of ECAR (Figure 4A). Moreover, inhibition of glycolysis induced CD8+ T cells to preferentially use OXPHOS as a source of energy, as revealed by a higher OCR/ECAR ratio in 2DG-treated CD8+ T cells (Figure 4A), but it did not enhance OXPHOS, as basal OCR was also reduced compared with control cells (Supplemental Figure 8). Consistent with recent findings (39), 2DG treatment triggered the activity of AMPK, as manifested by increased levels of AMPK phosphorylation (Figure 4B). AMPK is a well-established negative regulator of mTOR activity, which is required to sustain glucose uptake and glycolysis in CD8+ T cells via induction of the hypoxia-inducible factor 1 (Hif1) transcription factor complex (40). Accordingly, Hif1-α protein levels were decreased in CD8+ T cells treated with 2DG (Figure 4B). Finally, the mRNA levels of key enzymes and transporters involved in the glycolytic machinery were also reduced (Figure 4C), which indicates that 2DG not only inhibits glycolysis, but also triggers the activation of starvation signaling, which then reinforces shutdown of the glycolytic machinery at a transcriptional level.

To determine whether manipulating glycolysis during T cell priming modulates CD8+ T cell fate, we evaluated the transcriptional program and phenotype of differentiating CD8+ T cells. We assessed the expression levels of key transcriptional regulators implicated in memory T cell and Teff formation, such as Tcf7, Lef1, Bcl6, and Prdm1, as well as T cell differentiation markers, including CD44, CD62L, CD27, and KLRG-1. 2DG-treated T cells displayed increased mRNA levels of Bcl6, Tcf7, and Lef1, while control cells were enriched in Prdm1 mRNA (Figure 5A). Additionally, 2DG prevented the induction of effector molecule–encoding genes, such as Prf1 and GzmB (Figure 5A). Thus, gene transcription analysis provided evidence that blockade of glycolysis by 2DG enforces a transcriptional program characteristic of memory cells. Moreover we observed that 2DG-treated T cells retained higher expression of CD62L, a molecule found in Tns and early memory T cell subsets, compared with control cells (Supplemental Figure 9). To test whether inhibition of glycolysis during T cell priming programs CD8+ T cells to adopt a diverse fate in vivo, we transferred 2DG-treated pmel-1 CD8+ T cells into wild-type mice infected with gp100-VV and evaluated the expansion, persistence, and phenotypic changes of transferred cells. 2DG-treated CD8+ T cells expanded robustly, as indicated by increased frequencies and numbers of CD8+ Thy-1.1+ T cells in the spleen at the peak of the immune response compared with control cells (P < 0.01; Supplemental Figure 10, A and B). Despite increased expansion, a higher proportion of 2DG-treated cells retained a memory phenotype, whereas the majority of control CD8+ T cells underwent terminal differentiation, as revealed by the loss of CD62L and concomitant acquisition of the senescence marker KLRG-1 (Supplemental Figure 10, C and D). These quantitative and qualitative differences between 2DG-treated T cells and controls became more prominent during the memory phase of immune response. We observed 100-fold higher frequencies of pmel-1 CD8+ T cells in both lymphoid and nonlymphoid tissues of animals that received adoptive transfer of 2DG-treated versus control T cells (Figure 5, B and C). Notably, the persisting progeny of T cells primed in the presence of 2DG were relatively enriched in Tcms compared with control cells, which preferentially gave rise to senescent KLRG-1+ T cells (Figure 5D). Consistent with these findings, recall responses were significantly increased in mice that received adoptive transfer of 2DG-treated T cells (Figure 5, E and F). Together, these findings indicate that specific inhibition of glycolysis during priming enhances not only the quantity, but also the quality, of antigen-specific memory CD8+ T cells.
(Figure 6A). Phosphorylation of Foxo1 facilitates its binding to cytosolic 14-3-3 scaffold proteins, which prevents translocation of Foxo1 into the nucleus, thus resulting in a loss of Foxo1 transcriptional activity (42). Consistently, we found that the majority of Foxo1 protein was sequestered into the cytoplasm after CD8+ T cell stimulation, while treatment with 2DG promoted Foxo1 nuclear localization (Figure 6B).

To confirm that changes in Foxo1 compartmentalization resulted in differences in Foxo1 transcriptional activity, we measured the expression of Kruppel-like factor 2 (Klf2), a well-characterized Foxo1 target gene (43, 44). Quantitative RT-PCR analysis revealed that while control cells displayed low levels of Klf2 expression, 2DG treatment resulted in a dose-dependent increase in Klf2 and its target genes, such as selectin L (SelL; which encodes CD62L), chemokine (C-C motif) receptor 7 (Ccr7), and sphingosine-1-phosphate receptor 1 (S1pr1), which control the ability of T cells to home to secondary lymphoid structures (Figure 6C and refs. 44, 45). Finally, to determine whether modulation of glucose metabolism could regulate such lymphoid homing behavior, we adoptively transferred congenically marked control (Thy-1.1+) or 2DG-treated (Ly5.1+ Thy-1.1+) cells in the same hosts and evaluated the presence of transferred cells in both lymphoid and peripheral tissues 24 hours later. Strikingly, CD8+ T cells treated with 2DG exhibited 10-fold greater migration to lymph nodes compared with control cells, whereas both groups were found at similar frequency in lungs (Figure 6, D and E). Our results indicate that sustained glycolytic activity is required to maintain cell migratory properties characteristic of cytotoxic effector T lymphocytes and that direct blockade of glycolysis reprograms T cells to preferentially migrate to lymphoid tissues.
Glycolysis blockade enhances intratumoral T cell responses and augments antitumor functionality. Studies in both tumor (46, 47) and chronic viral (48) models have demonstrated that CD8+ T cells with the capacity to home to secondary lymph nodes, where they can be effectively stimulated by professional antigen-presenting cells, are more effective in adoptive immunotherapy. Furthermore, the ability of T cells to robustly proliferate and persist in the long term after transfer has been correlated with effective antitumor responses in mice and humans receiving adoptive T cell–based therapies (4, 5, 49–51). Thus, we hypothesized that tumor treatment could be improved by inhibiting glycolytic metabolism in tumor-specific T cells during ex vivo expansion. pmel-1 CD8+ T cells were primed with cognate gp100 peptide antigen, in the presence or absence of 2DG, and adoptively transferred into wild-type mice bearing large vascularized B16 melanoma tumors. At 3 days after transfer, tumor-specific T cells infiltrated the tumor bed at similar levels (Figure 7A), which indicates that inhibition of glycolysis during priming did not affect initial trafficking to tumors. However, with time, 2DG-treated cells more efficiently accumulated within the tumors (Figure 7A). Notably, within the tumors, T cells primed in the presence of 2DG acquired glycolytic ability, as manifested by the high expression of key glycolytic enzymes (Figure 7B). Consistently with a recent report indicating that glycolysis facilitates full effector functions (18), 2DG-treated cells exhibited increased production of IFN-γ and TNF-α compared with control cells after adoptive transfer (Figure 7C). Importantly, in vitro 2DG treatment of pmel-1 CD8+ T cells significantly augmented their in vivo antitumor activity, resulting in improved tumor regression (Figure 7D). Consequently, mice that received 2DG-treated cells exhibited prolonged survival (P < 0.01; Figure 7E). Thus, specific inhibition of glycolysis by 2DG in tumor-specific CD8+ T cells promoted the formation of memory CD8+ T cells under physiological conditions and augmented their antitumor function in mice bearing large vascularized tumors.

**Discussion**

Diverse metabolic changes accompany CD8+ T cell activation (9, 11). For instance, after antigen stimulation, T cells switch to glycolytic metabolism to sustain effector function (18). Metabolic reprogramming to glycolysis, however, has been found to be dispensable for proliferation or survival of T cells in the short term in vitro studies in the presence of alternative fuel (18). Whether specific changes in glucose metabolism can influence long-term survival of activated T cells and their capacity to enter into the memory pool in vivo remains unknown. In this study, we found that graded levels of glycolysis can act as a metabolic rheostat determining the decision between memory and terminal effector differentiation in CD8+ T cells. This conclusion was supported by 3 main lines of evidence. First, activated CD8+ T cells sorted on the basis of intrinsic differences in glucose metabolism experienced a divergent fate in vivo: CD8+ T cells displaying high glycolytic activity tended to be short-lived, whereas cells with low glycolytic metabolism established memory. Second, enforcing glycolysis by overexpression of Pgam1 severely impaired the ability of CD8+ T cells to persist in the long term and form memory in vivo. Finally, specific inhibition of glycolytic flux using 2DG during T cell priming enhanced the ability of CD8+ T cells to become long-lived memory cells.

The finding that graded levels of glycolytic flux can act as a metabolic rheostat to regulate CD8+ T cell fate determination has parallels in CD4+ T cell biology. High levels of glycolytic activity were found in polarizing conditions that sustain effector differentiation among effector cell subsets, such as Th1, Th2, and Th17, but were not observed during the generation of Tregs, which instead displayed elevated rates of lipid oxidation (37, 38). Accordingly, blockade of glycolysis using 2DG during T cell priming enhanced the ability of CD8+ T cells to become long-lived memory cells.

It has recently been established that the formation of memory CD8+ T cells can be enhanced by augmenting OXPHOS (11). For instance, overexpression of Cpt1a, a rate-limiting enzyme in FAO, increases memory CD8+ T cell numbers (22). It should be pointed out, however, that our results obtained by manipulation of glucose metabolism did not merely result from an enhancement in OXPHOS as a compensatory mechanism in response to
glycolytic shutdown, but were likely dependent on enforcement of cellular quiescence secondary to activation of glucose starvation signaling. Indeed, in all experimental settings used in the present studies, activated CD8+ T cells that were prone to form memory exhibited a lower overall bioenergetic profile, characterized not only by reduced levels of ECAR, but also by basal levels of OCR not exceeding those found in highly glycolytic cells.

Consistent with this view, we found that inhibition of glycolysis using 2DG was associated with increased activity of AMPK, an evolutionarily conserved protein kinase that enforces quiescence to limit energy demands in response to energy stress (9). Recently, AMPK has emerged as a key regulator of memory CD8+ T cell formation. For example, AMPKα1-deficient T cells were found to have profound defects in their ability to generate memory CD8+ T cell responses during Listeria monocytogenes infection (39), whereas pharmacologic activation of AMPK with metformin resulted in T cell responses during Listeria monocytogenes infection (39), where-
In *vitro* activation of T cells. CD8+ T cells from pmel-1 mice were stimulated in vitro with 1 μM hgp10025–33 peptide or plate-bound anti-CD3 (2 μg/ml; 145-2C11; BD Biosciences) and soluble anti-CD28 (1 μg/ml; 37.5 l; BD Biosciences) and expanded in culture medium containing 10 ng•ml⁻¹ IL-2 (Chiron) for 4 days. T cells were incubated with 2DG (Sigma-Aldrich) or vehicle (culture media) at indicated doses in the main text and figure legends. CD8+ T cells from C57BL/6 mice were stimulated using plate bound anti-CD3 and soluble anti-CD28 and expanded in culture medium containing 10 ng•ml⁻¹ IL-2 (Chiron) for 4 days.

Adoptive cell transfer, infection, recall response, and tumor experiments. Adoptive transfer of purified CD8+ T cells and infection with gp100-VV were performed as previously described (4). Recall response experiments were performed 30 days after primary infection with gp100-VV by rechallenging mice with 10⁶ pfu ad-gp100. Tumor experiments were performed using 10⁶ activated pmel-1 Thy-1.1 CD8+ T cells as previously described (4).

**Cell proliferation assay.** We labeled pmel-1 splenocytes with 5 μM Cell proliferation dye eFluo670 (eBioscience), stimulated in vitro with 1 μM hgp10025–33 peptide, and expanded in culture medium containing 10 ng•ml⁻¹ IL-2 for 4 days. Dilution of Cell proliferation dye was then evaluated by flow cytometry.

**Antibodies, flow cytometry, and cell sorting.** Mouse antibodies specific for anti-CD8α (53-6.7), anti-Thy-1.1 (OX-7), anti-CD44 (IM7), anti-CD62L (MEL-14), anti-CD25 (PC61), anti-CD27 (LG.3A10), anti–IFN-γ (554413), anti–TNF-α (MP6-XT22), and anti–KLRG-1 (2F1) were from BD Biosciences. Mouse antibody specific for anti-CD69 (H1.2F3) was from eBioscience. FACS Canto I or FACS Canto II (BD Biosciences) was used for flow cytometry acquisition. Samples were analyzed with FlowJo software (TreeStar). Cells were sorted on the basis of 2-NBDG levels with a FACS Aria instrument (BD Biosciences).

**OCR and ECAR.** OCR and ECAR were measured at 37°C using an XF24 extracellular analyzer (Seahorse Bioscience) as previously described (22). Briefly, cells were initially plated to unbuffered DMEM (DMEM with 25 mM glucose as indicated, 1 mM sodium pyruvate, 32 mM NaCl, 2 mM GlutaMax, pH 7.4) and incubated in a non-CO₂ incubator for 30 minutes at 37°C. ECAR and OCR were calculated using Seahorse XF-24 proprietary software. In experiments evaluating the acute response to glucose supplementation, we used media with 0 mM glucose and add 25 mM glucose at the indicated time point through the injection port.

**Real-time RT-PCR.** We isolated RNA with the RNeasy mini kit (Qiagen) and generated cDNA by reverse transcription (Applied Biosystems). Real-time RT-PCR was performed for all genes with primers from Applied Biosystems. We calculated relative to Actb.

**Retroviral vector construction and virus production.** Pgam1 cDNA sequence was cloned into retroviral MSCV vector that has GFP as a reporter gene (Addgene 9044). Platinum Eco cell lines (Cell Biolabs) were used for gamma retroviral production by transfection with DNA plasmids through the use of Lipofectamine 2000 (Invitrogen), and virus was collected 48 hours after transfection.

**In *vitro* transduction of CD8+ T cells.** Mouse CD8+ T cells were separated from non-CD8+ T cells with a MACS negative selection kit (Miltenyi Biotech) and activated on plates coated with anti-CD3 (2 μg/ml; 145-2C11; BD Biosciences) and soluble anti-CD28 (1 μg/ml; 37.5l; BD Biosciences) in cell culture media containing IL-2 (10 ng/ml; Chiron). Virus were “spin-inoculated” at 2,000 g for 2 hours at 32°C onto plates coated with retronectin (Takara). CD8+ T cells were activated for 24 hours and transduced as previously described (33). 72 hours after retroviral transduction, GFP+ cells were sorted with a flow cytometer and used for adoptive transfer experiments.

**Immunoblot analysis.** Western blot analysis was performed using standard protocols. Proteins were separated by 4%–12% SDS-PAGE, followed by standard immunoblot analysis using anti–Hif1α (R&D Biosciences), Hk2, p-AMPK, p-Foxo1/3a, total Foxo1, tubulin, and anti–β-actin (Cell Signalling). A 1:1,000 dilution was used for all antibodies.

**Cell fractionation and protein analysis.** Cytosolic and nuclear fractionation to study the subcellular distribution of Foxo1 were performed as described previously (55).

**Enumeration of adoptively transferred cells.** We euthanized mice at the indicated time points after infection. Splenocytes were enumerated by trypan blue exclusion. The frequency of transferred T cells was determined by measuring CD8 and Thy-1.1 or GFP with flow cytometry. The absolute number of pmel-1 cells was calculated by multiplying the total cell count by the percent CD8+Thy-1.1+.

**Metabolomics.** Using a flow cytometer, we purified Tns (CD8+CD44⁺ CD62L⁻) and Teffs (CD8+CD44⁺ CD62L⁺) generated after priming pmel-1 CD8+ T cells with hgp10025–33 peptide for 5 days. 6 biological replicates of Tns and Teffs were analyzed. Samples were split for separate analysis on GC/MS and LC/MS/MS platforms (see Supplemental Methods).

**Glucose uptake assays.** 2 x 10⁶ CD8+ T cells were incubated for 10 minutes in 500 μl glucose-free media. 500 μl glucose-free media containing 1 μCi/ml [¹⁴C] 2DG (Perkin Elmer) was then added, and cells were incubated for a further 20 minutes. Cells were pelleted, washed in PBS, and then lysed in water. Lysate 3H content was then measured via liquid scintillation counting. For flow cytometry–based glucose uptake assays, we incubated CD8+ T cells with 100 μM 2-NBDG (Invitrogen) for 2 hours before measuring fluorescence by flow cytometry.

**Statistics.** Data sets were compared using 1- or 2-tailed unpaired Student’s t test. A log-rank test was used for analysis of survival curves. For all analyses, a P value less than 0.05 was considered statistically significant.

**Study approval.** All animal experiments were conducted with the approval of the National Cancer Institute Animal Use and Care Committee (protocol SB-126).

**Acknowledgments**

This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The authors thank N. Acquavella, D. Clever, E. Tran, and M. Rao for critical review of the manuscript; A. Mixon, S. Farid, and G. Wiegand of the Flow Cytometry Unit for help with cell sorting; and D. Goldstein and M. Malik for catalyzing interactions with Metabolon. We sincerely thank Steven A. Rosenberg for his continuous support.

Received for publication February 27, 2013, and accepted in revised form July 24, 2013.

Address correspondence to: Madhusudhanan Sukumar, Center for Cancer Research, Surgery Branch, National Cancer Institute, NIH, Clinical Research Center, Room 3W-5816, Bethesda, Maryland 20892, USA. Phone: 301.451.0235; Fax: 301.451.6949; E-mail: sukumarm2@mail.nih.gov. Or to: Luca Gattinoni, Center for Cancer Research, Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, Clinical Research Center, Room 3E-3150, Bethesda, Maryland 20892, USA. Phone: 301.451.6914; Fax: 301.480.4354; E-mail: gattinol@mail.nih.gov.


